Information:
Fel:
ID
28248
Beskrivning
NCT02499003 The GOAL Trial: Rescue Treatment With the Monoclonal Anti CD20-antibody Obinutuzumab (GA101) in Combination With Pixantrone for the Treatment of Patients With Relapsed Aggressive B-cell Lymphoma. Study part: Informed consent (Screening) Source: Prof. Dr. med. Georg Heß Universitätsmedizin Mainz
Nyckelord
Versioner (4)
- 2017-11-25 2017-11-25 -
- 2017-11-25 2017-11-25 -
- 2017-11-30 2017-11-30 -
- 2017-12-31 2017-12-31 -
Rättsinnehavare
Prof. Dr. med. Georg Heß
Uppladdad den
31 december 2017
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Screening Informed consent GOAL Trial B-cell Lymphoma NCT02499003
Screening Informed consent GOAL Trial B-cell Lymphoma NCT02499003
Similar models
Screening Informed consent GOAL Trial B-cell Lymphoma NCT02499003
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Subject ID
Item
Subject ID
text
C2348585 (UMLS CUI [1])
Site Number
Item
Site No
text
C0018704 (UMLS CUI [1,1])
C0600091 (UMLS CUI [1,2])
C0600091 (UMLS CUI [1,2])
Screening number
Item
Screening no
text
C1710477 (UMLS CUI [1])
Informed consent availability
Item
Signed and dated informed consent of the patient is available before start of any trial specific procedures
boolean
C0021430 (UMLS CUI [1,1])
C0470187 (UMLS CUI [1,2])
C0470187 (UMLS CUI [1,2])
Date of informed consent
Item
Date of informed consent
date
C2985782 (UMLS CUI [1])
Study subject participation status
Item
Participation in contributing scientific investigations
boolean
C2348568 (UMLS CUI [1])